NL-OMON40014已完成不适用
Vaccination with minor histocompatibility antigen-loaded donor DC vaccines to boost graft-versus-tumor immunity after allogeneic stem cell transplantation (a phase I study) - MiHA-loaded DC vaccination after allogeneic SCT
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Patients with AML, myelodysplasia (MDS), ALL, CML (accelerated or blast phase), CLL, MM or malignant NHL, who underwent HLA-matched allo-SCT
- •* Patients positive for HLA-A2 and/or HLA-B7
- •* Patients positive for HA-1, LRH-1 and/or ARHGDIB transplanted with corresponding MiHA-negative donor
- •* Patients >18 and <65 years of age
- •* WHO performance 0-2
- •* Witnessed written informed consent
排除标准
- •* Life expectancy < 3 months;* Severe neurological or psychiatric disease;* Progressive disease needing cytoreductive therapy;* HIV positivity;* Patients with acute GVHD grade 3 or 4;* Patients with extensive chronic GVHD;* Patients with active infections (viral, bacterial or fungal) that requires specific therapy. Acute anti-infectious therapy must have been completed within 14 days prior to study treatment;* Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or symptomatic ischemic heart disease;* Severe pulmonary dysfunction (CTCAE III-IV);* Severe renal dysfunction (serum creatinine > 3 times normal level);* Severe hepatic dysfunction (serum bilirubin or transaminases > 3 times normal level);* Patients with known allergy to shell fish
研究者
相似试验
进行中（未招募）
1 期
Dendritic cells vaccination after allogeneic stem cell transplantatioPatients with aggressive hematological malignancies treated with allogeneic stem cell transplantationEUCTR2012-002879-34-NLRadboud University Nijmegen Medical Centre
尚未招募
不适用
MiHA-DC vaccinatie na allogene stamceltransplantatie.Patients with AML, MDS, ALL, CML (accelerated or blast phase), CLL, MM or malignant NHL, who underwent HLA-matched allo-SCT.NL-OMON29214Radboud University Nijmegen Medical Centre
已完成
不适用
Vaccination with human minor H antigen (HA-1) peptide after allogeneic stem cell transplantatioISRCTN80896844eiden University Medical Centre (LUMC) (Netherlands)24
已完成
1 期
Predetermined Minor Histocompatibility Antigen-based Therapeutic or Prophylactic Peptide Vaccinations for Patients with Recurred Malignancies or Patients with High-Risk Malignancies Follwoing Allogeneic Hematopoietic Cell Transplantation.(1) Therapeutic vaccine: Any hematological malignancies recurred after allogineic hematopoietic transplanation as follows (RAEB, CMML, AML, ALL, CML, Multiple Myeloma, NHL). (2) Prophylactic vaccine: Hematological malignancies with high risk of relapse after allogineic hematopoietic transplanation as follows (RAEB, CMML, AML in >=3CR/non-CR or any AML with M0/M6/M7 FAB type, ALL in >=2CR/non-CR, CML in >=2CP or >=AP, Multiple Myeloma in PD, NHL in non-CR).JPRN-UMIN000000872Aichi Cancer Center Research Institute12
进行中（未招募）
不适用
Donor Dendritische Cellen vaccinatie bij hematologische maligne aandoeningeEUCTR2012-002435-28-NLniversity Medical Center Utrecht